Video

What the re:Vive 2.0 platform may mean for the future of vision diagnostics

Author(s):

Sheryl Stevenson

Mary Durbin, PhD, Chief Scientific Officer at Heru, discusses the benefits and capabilities of the various testing modalities available in 1 wearable platform.

Mary Durbin, PhD, Chief Scientific Officer at Heru, discusses the benefits and capabilities of the various testing modalities available in 1 wearable platform with Sheryl Stevenson, Ophthalmology Times®’ Group Editorial Director.

Related Videos
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
AAO 2024: Matt Giegengack, MD: Injectable endothelial cell therapy shows promise for improving vision and reducing glare in corneal edema
Related Content
4DMT publishes preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform
December 20th 2024

4DMT publishes preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

eyeDNA Therapeutics receives FDA Rare Pediatric Disease Designation for HORA-PDE6b, a novel gene therapy for PDE6b retinitis pigmentosa
December 17th 2024

eyeDNA Therapeutics receives FDA Rare Pediatric Disease Designation for HORA-PDE6b, a novel gene therapy for PDE6b retinitis pigmentosa

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

EMA CHMP issues positive opinion for aflibercept biosimilar from Celltrion
December 16th 2024

EMA CHMP issues positive opinion for aflibercept biosimilar from Celltrion

Atsena Therapeutics completes dosing in Part A of phase I/II clinical trial evaluating ATSN-201 to treat X-linked retinoschisis
December 16th 2024

Atsena Therapeutics completes dosing in Part A of phase I/II clinical trial evaluating ATSN-201 to treat X-linked retinoschisis

© 2024 MJH Life Sciences

All rights reserved.